Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors or Meningiomas Expressing SST2A
Status:
Not yet recruiting
Trial end date:
2026-03-15
Target enrollment:
Participant gender:
Summary
This study will evaluate the safety and efficacy of Lutathera (177Lu-DOTATATE) in pediatric
and young adult patients with progressive or recurrent High-Grade Central Nervous System
(CNS) tumors and meningiomas (any grade) that express Somatostatin Type 2A Receptors by
immunohistochemistry and demonstrate uptake on DOTATATE PET. The drug will be given
intravenously once every 8 weeks for a total of up to 4 doses over 8 months in patients aged
4-12 years (Phase I) or older than 12 yrs (Phase II) to test its safety and efficacy,
respectively.